Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway

Hong-Zhi Sun*, Tong-Wei Yang1,*, Wei-Jin Zang and Shu-Fang Wu

Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, School of Medicine, Xi’an Jiaotong University, Xi’an 710061, People’s Republic of China
1First Affiliated Hospital of Jilin University, Changchun 130021, People’s Republic of China
(Correspondence should be addressed to S-F Wu; Email: shufangw@hotmail.com; H-Z Sun; Email: sunhongzhi@mail.xjtu.edu.cn)
*(H-Z Sun and T-W Yang contributed equally to this work)

Abstract

Dehydroepiandrosterone (DHEA) is an endogenous steroid that is metabolized to androgens and/or estrogens in the human prostate. DHEA levels decline with age, and use of DHEA supplements to retard the aging process is of unproved effectiveness and safety. In this study, rat ventral prostatic epithelial cells were used to determine whether DHEA-modulated proliferation and prostate-specific antigen (PSA) production were mediated via the androgen receptor (AR) and its potential mechanism. We demonstrated that proliferation of prostatic epithelial cells and increase of PSA expression induced by DHEA were neutralized by Casodex or Ar siRNA, two specific AR blockers. DHEA stimulated Nfkb DNA binding activity, with this effect being blunted by Casodex or Ar siRNA. Moreover, the inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT nullified the effects of DHEA on NFKB activation. These findings suggested that DHEA stimulated normal prostatic epithelial cell proliferation, and AR is involved in DHEA-induced PSA expression in normal prostatic epithelial cells. This stimulation effect induced by DHEA is mediated by the activation of NFKB via PI3K/AKT pathway. Journal of Endocrinology (2010) 204, 311–318

Introduction

Dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S are the most abundant steroids in humans, produced by the adrenal cortex (Labrie et al. 2001). The secretion of DHEA and DHEA-S by the adrenals increases during the adrenarche in children at the age of 6–8 years, and elevated values of circulating DHEA-S and DHEA are maintained throughout adult life, providing high levels of substrates for conversion into potent androgens and estrogens in peripheral tissues (Labrie et al. 1998). In the US, DHEA is widely available as an over-the-counter dietary supplement, and is increasingly self-prescribed for its alleged anabolic and anti-aging effects, with unsubstantiated claims of beneficial effects as well as uncertain long-term safety (Alesci et al. 2005).

In aged adults, the use of DHEA as a dietary supplement is of potential concern in that its androgenic or estrogenic actions may stimulate proliferation and other adverse effects in cancer cells within the prostate or breast (Arnold et al. 2005). DHEA is an important source of both androgenic and estrogenic ligands in the human prostate (Arnold 2009). DHEA-S is present in high levels in the prostate, as is the sulfatase that converts DHEA-S to DHEA (Klein et al. 1989). Receptors for DHEA or DHEA-S have not been definitively isolated (Widstrom & Dillon 2004). It was reported that DHEA acts on the direct agonistic and antagonistic effects on androgen receptor (AR), estrogen receptor (ER or ESR), and ERβ (ESR2) in human prostate cancer (PCa) and other cells (Chen et al. 2005).

AR is a member of the steroid receptor superfamily and is a nuclear transcription factor. Upon binding to AR, androgen activates AR, which, in turn, interacts with androgen response elements (ARE) in the promoter of target genes including prostate-specific antigen (PSA), regulating the transcription of target genes. It has been known that there are NFKB binding sites in the promoter of AR (Zhang et al. 2004), suggesting that NFKB may regulate the expression of AR. The activation of AKT and NFKB has been involved in the progression of PCa from androgen dependence to independence (Murillo et al. 2001, Kikuchi et al. 2003).

The phosphatidylinositol 3-kinase (PI3K)/AKT cell signaling pathway is an important regulator of growth and survival in many cell types including prostate. Although the relationship between AR and PI3K/AKT remains controversial, a variety of mechanisms have been suggested to account for how AKT influences AR, signaling pathways. These include the followings: 1) AKT directly interacts with AR and then suppresses AR activity (Lin et al. 2001, Yang et al. 2003a,b); 2) AKT directly interacts with AR and then enhances AR activity in a ligand-independent manner.
(Wen et al. 2000); 3) AKT indirectly enhances AR transactivation via the inhibition of GSK3B, the downstream substrate of PI3K/AKT, protein kinase A, and mitogen-activated protein kinase; GSK3B was found to suppress directly AR transactivation (Wang et al. 2004); and 4) AKT indirectly enhances AR transactivation by inhibiting GSK3B to positively regulate β-catenin (Sharma et al. 2002). β-catenin has been reported as a ligand-dependent AR co-activator (Truica et al. 2000). How AKT influences AR may depend on cell physiological conditions. AKT can activate NFKB pathway via phosphorylation and activation of molecules in the NFKB pathway (Ozes et al. 1999, Romashkova & Makarov 1999).

It has been well known that the NFKB pathway plays an important role in the control of cell growth, differentiation, apoptosis, inflammation, stress response, and many other physiological processes in cellular signaling. The NFKB signaling pathway is also involved in the development and progression of PCa. NFKB is overexpressed in prostatic intraepithelial neoplasia and prostate adenocarcinoma (Sweeney et al. 2004). Constitutive activation of NFKB has been found in androgen-independent PCa cells, whereas less activity of NFKB has been observed in androgen-dependent PCa cells (Suh et al. 2002, Zerbini et al. 2003). Like AKT and AR, the relationship between NFKB and AR activation remains controversial. Palvimo et al. (1996) reported that elevated expression of NFKB p65 repressed AR-mediated transactivation in a dose-dependent manner, whereas NFKB p50 did not influence AR transactivation. However, other investigators have shown that IL4-induced NFKB is required for AR activation (Lee et al. 2005), and that there are NFKB binding sites in the promoter of AR (Zhang et al. 2004), suggesting that the activation of NFKB could enhance AR transactivation.

To clarify these issues, we studied the direct effect of DHEA on primary cultured rat prostatic epithelial cells in the presence/absence of Casodex and Ar siRNA, both of which are recognized blockers of AR. We have analyzed the effect of DHEA on epithelial cell proliferation and the activity of downstream gene products playing a prominent role in prostatic epithelial cells. Our results show that DHEA stimulated PI3K/AKT activity and finally activates the pro-survival transcription factor NFKB in prostatic epithelial cells.

Materials and Methods

Rat ventral prostate epithelial cell culture

Primary culture of rat prostatic epithelial cells was carried out as described previously: prostates were taken from 6-week-old animals (Taketa et al. 1990). Cells were cultured in 2 ml of a medium consisting of RPMI-1640 (Gibco) supplemented with 10% fetal bovine serum, glutamine 2 mmol/l, penicillin 100 kU/l, streptomycin 100 mg/l, epidermal growth factor 10 µg/l, cholera toxin 10 µg/l, and transferrin 5 mg/l. Cultures were incubated in a humidified atmosphere of 5% carbon dioxide and 95% air at 37 °C. Upon reaching monolayer confluence, the cells were split by treatment with 0.25% trypsin solution to give a final concentration of 5 × 10^4 cells/ml with PBS before starvation in 0.1% BSA (fraction V, Sigma), phenol red-free and serum-free RPMI-1640 for further 24 h, and the following tests were carried out.

In this study, DHEA, dihydrotestosterone (DHT), and Casodex (bicalutamide) were all purchased from Sigma–Aldrich.

3H-thymidine incorporation

To assess cell proliferation in prostatic epithelial cells, we measured 3H-thymidine incorporation into newly synthesized DNA. At the end of the culture period, 2.5 µCi/well of 3H-thymidine (25 Ci/mmol; Amersham) was added to the culture medium for an additional 3 h. Cells were released by trypsin and collected onto glass fiber filters. Incorporation of 3H-thymidine was measured by liquid scintillation counting. Five replicates per condition were assayed, and data expressed as mean ± S.E.M. from three separate experiments were presented.

Ar siRNA transfection

Prostatic epithelial cells were transfected with siRNA targeted for AR (Santa Cruz Biotechnology, Santa Cruz, CA, USA). We used a pool of four target-specific, 20–25 nucleotide-long siRNAs designed to knock down AR gene expression. Sense strand (A): CUG AGU AUU CCU CUU UCA A; sense strand (B): CAG UCC CAA UUG UGU CAA A; sense strand (C): CCA GAA GAU GAC UGU AUC A; sense strand (D): GAC UGU AUC ACA CAU UGA A. An siRNA consisting of a scrambled sequence was similarly transfected as control. siRNA was introduced to cells using Lipofectamine 2000 (Invitrogen Corporation), according to the procedure recommended by the manufacturer. One day before transfection, the cells were plated in 500 µl growth medium without antibiotics such that they were 30–50% confluent at the time of transfection. The transfected cells were cultured in DMEM containing 10% FCS for 72 h after transfection.

To determine transfection efficiency, we transfected prostatic epithelial cells with FITC-conjugated control siRNA (Santa Cruz Biotechnology) in two separate experiments. Transfection efficiency was 57.0 ± 3.1% (range of 46.8–60.4%). To demonstrate the specific inhibitory effect of Ar siRNA on AR expression, we evaluated Ar mRNA and protein expression in transfected prostatic epithelial cells by real-time PCR and western blot respectively.

Real-time PCR

At the end of the culture period, total RNA was extracted from prostatic epithelial cells using the Qiagen RNeasy Mini kit (Qiagen Inc.). The recovered RNA was further processed using 1st Strand cDNA synthesis kit for RT-PCR.
DHEA-induced PSA expression · H-Z Sun, T-W Yang and others

P<0.05 vs control; #P<0.05 vs DHEA

Figure 1 Effect of DHEA on rat prostatic epithelial cell proliferation. Rat prostatic epithelial cells were treated with DHEA in the presence of Casodex (A) or Ar siRNA (B) for 24 h. At the end of the culture period, 2.5 μCi/well of 3H-thymidine was added to the culture medium for an additional 3 h. Cells were released by trypsin and collected onto glass fiber filters. Incorporation of 3H-thymidine was measured by liquid scintillation counting. Data were expressed as percentage of control (mean ± S.E.M.) and were obtained from three separate experiments.

PI3K assay
PI3K activities were determined by an in vitro kinase assay (SuperArray Bioscience Corporation, Frederick, MD, USA), according to manufacturer’s instructions. Cells were seeded into 96-well plates and incubated with DHEA, DHT and/or Casodex, and/or Ar siRNA for 24 h. Cells were then fixed with 4% formaldehyde for 20 min at room temperature to preserve phosphorylation. The relative extent of target protein phosphorylation is determined by normalizing absorbance reading of the phosho-protein specific antibody to the pan-protein specific antibody for the same experimental condition. Experiments were performed more than three times, and data were expressed as percentage of control.

Nfκb p65 transcription factor assay
Nfκb p65 transcription factor activity was determined by an ELISA (Cayman Chemical, Ann Arbor, MN, USA), according to the manufacturer’s instructions. Nuclei were extracted from prostatic epithelial cells treated for 24 h with 100 nM DHEA, 100 nM DHT, and/or the following specific protein kinase inhibitors: Wortmannin (PI3K inhibitor); Akti-1/2 (AKT inhibitor). All these inhibitors (EMD Chemicals, Gibbstown, NJ, USA) have previously been shown to be specific inhibitors (Bain et al. 2007). Data are expressed as absorbance at 450 nm/μg protein. The results are expressed as the mean ± S.E.M. of three separate experiments.

Animal treatment
All animals used in these studies were maintained in compliance with the Animal Experiments Guidelines and Animal Care of Chinese Academy of Sciences. Sprague–Dawley male rats of age 6 weeks were housed in groups of two per individual microisolator cage under controlled temperature (21–22 °C), humidity (50%), and light conditions (12 h light:12 h darkness cycle; lights on at 0700 h).

Electrophoretic mobility shift assay
Nuclear protein extract was prepared from cultured prostatic epithelial cells (Wu et al. 2001). NFKB binding activity was studied by using double-stranded oligonucleotides (5′AGT TGA GGG GAC TTT CCC AGG C-3′, corresponding to the consensus NFKB binding site, Promega). The oligonucleotide probe was prepared by phosphorylation with T4 polynucleotide kinase (Promega Corporation) in the presence of [γ-32P] ATP (Amersham Biosciences), followed by inactivation of the kinase by adding 1 μl of 0.5 M EDTA. Nuclear proteins (10 μg) were preincubated for 10 min in NFKB binding buffer (Promega). Radioactively labeled oligonucleotide was added, and the mixture was incubated for 30 min at room temperature. The complexes were then subjected to 6% nondenaturing acrylamide gel, electrophoresed, and analyzed by autoradiography. To assess the specificity of the Nfκb DNA binding, competition experiments were performed by using excess (10 X) of unlabeled Nfκb oligonucleotides and nonspecific competitor DNA sequence (SP1).

Western blot
Whole cell lysates were solubilized with 1% SDS sample buffer and electrophoresed on a 4–15% SDS-PAGE gel (Bio–Rad). Proteins were transferred onto a nitrocellulose membrane and were probed with the following primary antibodies: rabbit polyclonal antibodies against β-actin and AKT (Santa Cruz) and goat polyclonal antibody against PSA (Santa Cruz). The blots were developed using a HRP-conjugated polyclonal goat-anti rabbit IgG or a donkey anti-goat IgG antibody and enhanced chemiluminescence system (Amersham). The protein size was confirmed by molecular weight standards (Invitrogen). The intensity of the bands on western blots was analyzed by Image J (software from NCBI; http://rsb.info.nih.gov/ij/). Results were expressed as percentage control siRNA-transfected cells and were obtained from three separate experiments.

Electrophoretic mobility shift assay
Nuclear protein extract was prepared from cultured prostatic epithelial cells (Wu et al. 2001). NFKB binding activity was studied by using double-stranded oligonucleotides (5′AGT TGA GGG GAC TTT CCC AGG C-3′, corresponding to the consensus NFKB binding site, Promega). The oligonucleotide probe was prepared by phosphorylation with T4 polynucleotide kinase (Promega Corporation) in the presence of [γ-32P] ATP (Amersham Biosciences), followed by inactivation of the kinase by adding 1 μl of 0.5 M EDTA. Nuclear proteins (10 μg) were preincubated for 10 min in NFKB binding buffer (Promega). Radioactively labeled oligonucleotide was added, and the mixture was incubated for 30 min at room temperature. The complexes were then subjected to 6% nondenaturing acrylamide gel, electrophoresed, and analyzed by autoradiography. To assess the specificity of the Nfκb DNA binding, competition experiments were performed by using excess (10 X) of unlabeled Nfκb oligonucleotides and nonspecific competitor DNA sequence (SP1).
Animals were fed a commercially available chow, and water was available ad libitum. Castration was performed via a scrotal incision under ether anesthesia before starting the experiment. Both the testes and epididymis were removed. After castration, the rats were maintained under standard laboratory conditions for 7 days. Then the animals were randomized according to their body weights and were assigned to three groups of 9–10 animals each as follows: 1) gonadectomized (GDX) control; 2) GDX C DHEA (3 mg/rat diet) and 3) GDX C DHT (0.1 mg/rat). DHEA or DHT suspended in 5% ethanol–0.4% methylcellulose was administered s.c. once a day at 0800 h, while GDX control group received vehicle alone during the same time period. The volume of an individual gastric feeding was 1.0 ml/100 g body weight every day for 30 days. Prostates of ten rats in each group were obtained for investigation 24 h after the last administration. After weighing, RNA and protein were extracted from ventral prostate, and Psa mRNA and protein levels were determined by quantitative RT-PCR and western blot. Experiments were performed twice, and data were expressed as fold of control.

Statistical analysis

Statistical differences were determined by a Student’s t-test. A P value <0.05 was considered significant. Values are the mean ± S.E.M.

Results

Effect of DHEA on prostatic epithelial cell proliferation

Prostatic epithelial cell cultures were treated with 100 nM DHEA for up to 24 h. When compared with control, DHEA exhibited increased cell proliferation (assessed by total 3H-thymidine incorporation, 154.6 ± 6.8% of control, P<0.05, Fig. 1A), while addition of Casodex neutralized this stimulating effect induced by DHEA (DHEA + Casodex versus DHEA: 114.3 ± 4.7 vs 154.6 ± 6.8% of control, P<0.05; Fig. 1A). Blocking AR by Ar siRNA inhibited DHEA-induced proliferation of prostatic epithelial cell similar to that observed using pharmacological blockade by Casodex (DHEA + Ar siRNA versus DHEA: 106.8 ± 4.2 vs 154.6 ± 6.8% of control, P<0.05, Fig. 1B). Diminished Ar mRNA (0.46 ± 0.05-fold compared with control, P<0.01, Fig. 2A) and protein levels (0.58 ± 0.06-fold compared with control, P<0.01, Fig. 2B) represented by real-time PCR and western blot confirm effectiveness of Ar siRNA.

Effect of DHEA on Psa mRNA and protein expression on prostatic epithelial cell

PSA is a clinically important marker used to monitor diagnosis, treatment response, prognosis, and progression in patients with PCa (Zhang et al. 2004). To investigate whether androgenic pathways involved in DHEA-mediated effects in prostate cells, Psa gene and protein expression were evaluated in the absence and presence of AR antagonists, Casodex or...
Ar siRNA. DHEA significantly increased Psa mRNA 6.7 ± 0.25-fold of control, an effect blocked by Casodex or Ar siRNA (3.2 ± 0.35 and 2.1 ± 0.21-fold of control respectively; Fig. 3A, P < 0.05). PSA protein expression was stimulated 5.3 ± 0.17-fold of control by DHEA, whereas co-treatment with Casodex or Ar siRNA decreased DHEA-stimulated PSA levels to 2.8 ± 0.24 and 2.1 ± 0.16-fold of control respectively (Fig. 3B).

Effect of DHEA on Nfkb DNA binding activity

To determine whether the DHEA-mediated proliferation led to an increase of NFKB activation, we studied the binding of NFKB to DNA by performing electrophoretic mobility shift assay. Epithelial cells isolated from rat prostate were cultured up to 24 h with or without DHEA in the presence or absence of Casodex or Ar siRNA, and nuclear extracts were then prepared. Labeled oligonucleotides containing a NFKB consensus sequence were incubated with prostatic cells nuclear extract, leading to the formation of a protein–DNA complex. DHEA stimulated formation of the NFKB–DNA complex at 24 h of culture, with this effect being neutralized by addition of Casodex or Ar siRNA. To confirm specificity, Nfkb DNA binding was competed out with a NFKB cold probe but not with the SP1 cold probe (Fig. 4A). Similarly, formation of the NFKB–DNA complex stimulated by DHT was also neutralized by addition of Casodex or Ar siRNA.

Effect of DHEA on PI3K/AKT signaling pathway

Previous studies identified a PI3K/c-AKT/Pak1/NFKB cell survival pathway in DU-145 PCs and Madin–Darby canine kidney epithelial cells (Cleutjens et al., 1996). To determine if intracellular signaling pathway(s) PI3K/AKT are involved in prostatic epithelial cell physiology, we first determined PI3K/AKT activity in prostatic epithelial cells treated by DHEA or DHT in the presence or absence of Casodex or Ar siRNA. DHEA stimulated PI3K/AKT dramatically (179.4 ± 10.3% of control, P < 0.05), with this stimulation being neutralized by the addition of Casodex or Ar siRNA (DHEA + Casodex versus DHEA: 126.6 ± 6.8 vs 179.4 ± 10.3% of control; DHEA + Ar siRNA versus DHEA: 110.3 ± 9.5 vs 179.4 ± 10.3% of control; P < 0.05, Fig. 4B and C). Similarly, stimulation of PI3K/AKT activity caused by DHT (197.4 ± 8.7% of control, P < 0.01) was neutralized by the addition of Casodex or Ar siRNA (DHT + Casodex versus DHT: 116.6 ± 6.8 vs 197.4 ± 8.7% of control; DHT + Ar...
siRNA versus DHT: 108.7 ± 9.5 vs 197.4 ± 8.7% of control; P < 0.05, Fig. 4B and C). To confirm if PI3K/AKT mediates the effects of DHEA on NFκB p65 activity, we cultured epithelial cells in the presence of DHEA, with or without specific PI3K/AKT inhibitor. Both DHEA and DHT stimulated NFκB p65 DNA binding activity dramatically (DHEA: 168.8 ± 5.2% of control; P < 0.01; DHT: 189.9 ± 8.7% of control, P < 0.001). The addition of 10 μM wortmannin (a PI3K inhibitor) or 10 μM Akti-1/2 (AKT inhibitor) to the culture medium of DHEA-treated prostatic epithelial cells significantly reversed the stimulatory effects of DHEA on Nfκb p65 DNA binding activity (DHEA + Wortmannin versus DHEA: 115.6 ± 5.6 vs 168.8 ± 5.2% of control; P < 0.05; DHEA + Akti-1/2 versus DHEA: 106.4 ± 4.8 vs 168.8 ± 5.2% of control, P < 0.05; Fig. 4D). Similar to this finding, Wortmannin or Akti-1/2 also blocked NFκB activity induced by 100 nM DHT (DHT + Wortmannin versus DHT: 118.5 ± 8.6 vs 189.9 ± 8.7% of control; P < 0.01; DHT + Akti-1/2 versus DHT: 110.6 ± 9.4 vs 189.9 ± 8.7% of control, P < 0.05; Fig. 4D).

Effect of DHEA and DHT on PSA mRNA and protein expression of castrated rats

Male rats given DHEA daily for 30 days did not show any statistical difference in body weight (data not shown). Mean weight of ventral prostate weight (normalized to mg/100 g animal body weight) in GDX rats was significantly increased by chronic exposure to either DHEA or DHT (DHEA versus control: 23.9 ± 7.5 vs 9.6 ± 3.8, P < 0.05; DHT versus control: 31.4 ± 6.7 vs 9.6 ± 3.8, P < 0.01, Fig. 5A).

Both DHEA and DHT significantly increased Psa mRNA expression in prostate isolated from male rats, as evaluated by quantitative RT-PCR (4.6 ± 0.35- and 5.8 ± 0.27-fold versus control respectively, P < 0.05 DHEA versus control and P < 0.01 DHT versus control, Fig. 5B); furthermore, DHEA and DHT also induced a marked increase of PSA protein expression (3.9 ± 0.21-fold of control and 4.5 ± 0.13-fold of control respectively, P < 0.05; Fig. 5C).

Discussion

In the United States, DHEA is widely used as an over-the-counter dietary supplement on the basis of its purported, yet controversial, anti-aging benefits to improve body composition, endocrine-metabolic balance, immune and psychological functions, and quality of life (Svec & Porter 1998, Alesci et al. 2005). Because DHEA is a precursor of more potent androgens and estrogens, there is some concern that DHEA supplementation may promote PCa growth or deleterious functions in men with preexisting PCa (Acacio et al. 2004). This study aimed to evaluate the direct effects of DHEA on prostatic epithelial cells.

We found evidence to suggest that DHEA stimulated prostatic epithelial cells proliferation through AR. DHEA-induced proliferation of the prostatic epithelial cells was blunted by the addition of Casodex, an antagonist of AR or siRNA, indicating that the effect of DHEA on epithelial cells was by acting through AR. It was also reported that the AR antagonist, Casodex, inhibited DHEA-induced proliferation of LNCaP cells (Arnold et al. 2007). Interactions among androgens, estrogens, and their receptors contribute to normal prostate development and function (Prins et al. 1998, Risbridger et al. 2003, Ho 2004, Soronen et al. 2004), and to dysregulation of prostate growth, potentially promoting hormone-independent PCa (Arnold & Isaacs 2002, Heinlein & Chang 2004). In castrated rats, our result demonstrated that DHEA treatment had no significant effect in body weight. Consistent to our finding, previous studies have shown that administration of DHEA at dietary concentrations of up to ten times this level has no effect on body weight gain in Sprague–Dawley rats (McCormick et al. 1996). Previous in vivo study demonstrated that DHEA replacement had no significant effect on serum PSA level in healthy aged men (Jedrzejuk et al. 2003); DHEA-S serum levels were negatively correlated with patient age, sexual function score, total score, and PSA (Ponholzer et al. 2002). In our study, however, similar to the stimulation effect on prostate induced by DHT, a positive control, DHEA treatment for 30 days increased prostate weight, as well as Psa mRNA and protein expression level in prostate. Psa is a well-known AR-regulated gene in the human prostate gland, and is expressed principally by both normal prostate epithelium and hormone-dependent PCa cells. PSA is generally considered to be the most sensitive biochemical marker available for monitoring the presence of
prostatic disease, particularly PCa, and response to therapy (Heinlein & Chang 2004). The primary regulator of PSA expression is AR, which induces PSA expression through three ARE-containing enhancer elements located in the proximal 6 kb of the PSA promoter (Cleutjens et al. 1997). Our finding demonstrated that DHEA stimulated PSA on epithelial cells compared with untreated cells, while co-treatment with Casodex or siRNA neutralized such effect. In LNCaP cells, DHEA-stimulated PSA gene and protein expression were inhibited by Casodex. Blocking AR by Casodex or by siRNA inhibited the effects of androgenic hormones.

Previous studies identified a PI3K/c-AKT/Pak1/NFKB cell survival pathway in DU–145 PCa and Madin–Darby canine kidney epithelial cells (Ross et al. 2003). In clinical studies of PCa specimens, overexpression of NFKB/p65 protein was shown to be an independent predictor of poor prognosis in PCa patients (Fradet et al. 2004). In prostatectomy specimens of PCa with relapsed tumor, NFKB was found to be concentrated in the nuclear fraction (Ross et al. 2003). Therefore, effective inhibition of NFKB could be critical in providing a targeted pathway for PCa prevention. It was also observed that treatment of PC3 with delphinidin (fruit- and vegetable-derived chemopreventive agents) led to a dose-dependent decrease in the DNA binding potential of NFKB, thereby making it transcriptionally incompetent to drive the expression of target genes. In our study, DHEA-induced Nfkb DNA binding activity on prostatic epithelial cell proliferation and PSA expression was neutralized by addition of Ar siRNA. Using specific chemical inhibitors, we also demonstrate involvement of PI3K/AKT signaling in NFKB-mediated regulation of DHEA activities in prostatic epithelial cells. The PI3K/AKT cell signaling pathway is an important regulator of growth and survival in many cell types including prostate (Bellacosa et al. 1991, Nakatani et al. 1999). AKT can be activated by various growth factors by activating PI3K and subsequently phosphorylating AKT at Thr308 or Ser473 (Burgering & Coffer 1995, Franke et al. 2001). Reports on the role of NFKB in AR signaling are conflict. Some showed NFKB negatively regulates AR function (Palvimo et al. 1996), and others showed NFKB enhances AR-mediated PSA expression (Chen & Sawyers 2002). Our study clarified that under normal condition, NFKB activation facilitates DHEA-induced prostatic epithelial cell proliferation and PSA expression through PI3K/AKT pathway. In summary, our study demonstrates that DHEA stimulates prostatic epithelial cells proliferation and PSA expression by activating, at least in part, NFKB via the PI3K/AKT pathway.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the programs from the National Natural Science Foundation of China (Key Program, No. 30930105; General Program, No. 30971392), the National Basic Research Program of China (973 Program, No. 2007CB512005) and New Century Excellent Talents in University from Ministry of Education (NCET-08-0435) and ‘Tengfei’ supporting grant of Xi’an Jiaotong university.

References


Arnold JT & Isacs JT 2002 Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. *Endocrine-Related Cancer* 9 61–73.


Henlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276–308.


Widstrom RL & Dillon JS 2004 Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Seminars in Reproductive Medicine 22 289–298.


Received in final form 18 November 2009
Accepted 10 December 2009
Made available online as an Accepted Preprint 10 December 2009